Objective: T-stage is an imperfect prognostic indicator for patients with nasopharyngeal carcinoma. We evaluated the effect of extent of intracranial involvement on survival after conventional radiotherapy in patients with Stage T4 nasopharyngeal carcinoma. Methods: We conducted a retrospective analysis of the results of computed tomography, magnetic resonance imaging and treatment outcomes in 84 consecutive patients with Stage T4 nasopharyngeal carcinoma during the period September 1993 to December 2002 in Taiwan. The patients were subcategorized into those who had limited intracranial involvement ( primary nasopharyngeal tumors with involvement of the unilateral cavernous sinus or the parasellar region only) or extensive involvement (extension of the tumors to the bilateral cavernous sinus or the parasellar region, into the orbit and the ethmoid sinus anteriorly, or to the prepontine region and the posterior cranial fossa). Results: Extensive intracranial involvement was found in 51.2% of the patients. Among these patients, the 5-year rate of overall survival after conventional radiotherapy was only 3.4%. In contrast, the 5-year survival among patients with limited intracranial involvement was 42.9%. This difference was significant (P , 0.001). In the multivariate analysis, extensive intracranial involvement, advanced age and a nodal status of N3 correlated with poor overall survival (all P , 0.05). Conclusions: Among patients with T4 nasopharyngeal carcinoma, better treatment outcomes were associated with limited intracranial involvement. We conclude that a subdivision of Stage T4 nasopharyngeal carcinoma disease based on the extent of intracranial involvement would provide better prognostic information.
INTRODUCTION
The importance of staging systems to group patients with cancer according to prognosis and, thus, decide appropriate treatment protocols has been widely acknowledged. However, in the case of nasopharyngeal carcinoma (NPC), there is still room for improvement in the correlation between T-stage and prognosis (1 -3) . Numerous clinical trials have been performed in an attempt to define the optimal treatment regimens for patients with early-and latestage NPC, but the results have often been inconsistent (4 -8) . One reason for this may have been the inadequacy of the staging systems to accurately categorize patients into similar risk groups (2) , and some studies have shown that the T-stage as defined by the American Joint Committee on Cancer 5th Edition Criteria (AJCC, 1997) (9) carried no prognostic significance for patients with T3 and T4 or for patients with T2a and T2b NPC (10, 11) .
Owing to the early invasiveness and anatomic location of NPC, this disease is often not diagnosed before it has reached an advanced stage (12) . This means that the base of the skull is involved in 25 -35% of the cases, with intracranial invasion occurring in 3 -12% of the cases (13) . Tumors with intracranial extension and/or involvement of the cranial nerves, infratemporal fossa, hypopharynx or orbit have been defined as Stage T4 by the AJCC (9); and intracranial tumor involvement has been considered to be a significant barrier to achieving successful treatment. Thus, it is not surprising that the prognosis for patients with T4 tumors would be poor. However, we have found in our clinical experience that not all patients with intracranial involvement had a bad prognosis; and a small proportion of these patients achieved long-term survival after conventional radiotherapy. The work of Chang et al. (10) has shown that primary tumor volume was a more important prognostic factor for treatment than T-stage among patients with Stage T3 and T4 NPC. Rho et al. (14) found that patients with involvement of the anterior or posterior cranial nerves and intracranial extension had a worse prognosis than those with only erosion of the skull base. In the present study, we retrospectively reviewed patient data to determine whether the staging and prognosis of patients with T4 NPC could be further refined on the basis of the extent of intracranial involvement of NPC tumors as determined by computed tomography (CT) and magnetic resonance imaging (MRI). Therefore, we evaluated the effect of the extent of intracranial extension on patient survival after conventional radiotherapy and chemotherapy.
PATIENTS AND METHODS
We retrospectively reviewed radiologic findings and treatment outcomes of 84 consecutive patients with Stage T4 NPC with intracranial involvement treated during the period September 1993 through December 2002 at Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Patients with distant metastasis at diagnosis and those who did not complete the full course of radiotherapy were excluded. Tumors were staged with the AJCC 1997 staging classification for NPC on the basis of CT and MRI findings (9) . All patients included in the analysis had primary tumors without extension to the hypopharynx and no evidence of distant metastases before radiotherapy. All exhibited pure intracranial extension, and none showed involvement of the skull base only.
Patients were subcategorized according to the extent of intracranial involvement of their tumors as follows. Limited involvement was defined as a primary nasopharyngeal tumor with involvement of the unilateral cavernous sinus or the parasellar region only. Extensive involvement was defined as extension of the tumor to the bilateral cavernous sinus or the parasellar region, into the orbit and the ethmoid sinus anteriorly, or to the prepontine region and the posterior cranial fossa (Fig. 1) .
RADIOTHERAPY
All patients in this retrospective study had been treated by conventional radiotherapy with bilateral opposing fields of 6-megavoltage photons. The fields of exposure covered the primary tumor and regional lymphatic drainage, with limitation of escalating radiation doses when the tumor extended to critical organs such as the eyes, optic apparatus or brainstem. The spinal cord and brainstem were spared after exposure to 40 -45 and 50 -54 Gy, respectively. We reserved the use of a 9 MeV electron beam as a posterior neck boost. A separate anterior low-neck field with spinal cord shielding was administered to encompass the lower neck and the supraclavicular fossa. Conventional radiotherapy was administered five times a week at 1.8 -2.0 Gy per day. The median dose of radiation to the primary tumor was 72 Gy (range, 68 -76 Gy). No additional boost treatment was administered.
CHEMOTHERAPY
Before 1999, few patients with Stage T4 disease were treated with concomitant chemotherapy in our department and those who were usually had bulky lymph nodes. Since 1999, when the benefits of adding chemotherapy to radiotherapy were documented, most patients withT4 disease have concomitant chemotherapy recommended. In addition, neoadjuvant chemotherapy is considered if the patient has bulky lymph nodes (N3). Adjuvant chemotherapy is considered if the patient has bulky lymph nodes or lymph nodes close to the supraclavicular fossa and has good status after concurrent chemoradiotherapy (CCRT).
Thirty-one patients (36.9%) received radiation plus concomitant cisplatin-based chemotherapy. Eighteen of the patients received chemotherapy with cisplatin and 5-fluorouracil (5-FU) according to the following schedule: a course of cisplatin (60 mg/m 2 Â 1 day) and 5-FU (600 mg/m 2 Â 5 days) was planned to be given in week 1 and a second course was planned in week 6 (total of two courses). However, 7 of the 18 patients delayed the second course of chemotherapy more than 1 week: 4 because of Grade 3 mucositis and 3 because of leucopenia according to the RTOG-Acute Radiation Morbidity Scoring Criteria.
Because of severe acute toxicity (including leucopenia and mucositis) associated with concomitant chemotherapy with cisplatin plus 5-FU, 13 of the 31 patients were treated with cisplatin alone according to the following schedule: a course of 100 mg/m 2 was planned to be given in week 1 and a second course in week 4. However, 2 of the 13 patients delayed the second course of chemotherapy more than 1 week because of Grade 3 leucopenia.
FOLLOW-UP
All patients were evaluated by a physician for locoregional tumor recurrence, distant metastases and tumor or treatment-associated complications at 3-month intervals for
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New prognosis in T4 nasopharyngeal carcinoma the first 3 years, at 6-month intervals for years 4 and 5, and at 1-year intervals thereafter. All patients underwent either a CT scan (n ¼ 53, 63.1%) or an MRI scan (n ¼ 31, 36.9%) at 3-to 6-month intervals for the first 3 years and annually during years 4 and 5.
STUDY ENDPOINTS
The primary study endpoints were overall survival (OS), locoregional recurrence-free survival (LRRFS) and diseasefree survival (DFS). The OS duration was calculated from the first day of treatment until either the day of last follow-up or death. The LRRFS duration was calculated from the first day of treatment until LRR or until the day of last follow-up. The DFS duration was calculated from the first day of treatment until the date of LRR, distal metastasis, death or last follow-up, whichever occurred first.
STATISTICAL ANALYSIS
Continuous and categorical variables are presented as mean + standard deviation (SD) and number (with percentage). The Kaplan -Meier method was used to calculate the rates of OS, LRRFS and DFS and to generate survival curves. Differences between survival curves were established with the log-rank test or Breslow test. A possible effect of age on survival was tested by Cox's proportional hazard modeling. Multiple analyses with Cox's proportional hazard modeling were also performed to determine the effects of prognostic factors on outcome. A two-sided P value ,0.05 was considered statistically significant. All statistical analyses were performed with SPSS software version 15.0 (SPSS Inc., Chicago, IL, USA).
RESULTS

PATIENT CHARACTERISTICS
Ninety-five patients with Stage T4 NPC and intracranial involvement were treated at Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, during the period September 1993 through December 2002. Eleven patients with distant (Fig. 2) .
LOCOREGIONAL RECURRENCE-FREE SURVIVAL
As shown in Table 2 , LRR was significantly correlated with the Karnofsky index (P ¼ 0.004), pathology (P ¼ 0.038) and intracranial extension (P ¼ 0.001). After controlling for the effects of age and sex, extensive intracranial extension (HR ¼ 5.11, 95% CI 1.76 -14.89; P ¼ 0.003) was correlated with a significantly higher risk of LRR (Table 3) . Conversely, a Karnofsky index score of 80 diminished the risk of LRR (HR ¼ 0.29, 95% CI 0.10 -0.87; P ¼ 0.027).
The estimated median durations of LRR were 37.0 (SD ¼ 7.2, 95% CI ¼ 2.9 -51.1) months for the patients with extensive intracranial extension; more than half of the patients with limited intracranial extension did not have LRR at the end of study, so the median duration of LRR could not be estimated. The LRRFS rates of patients with limited intracranial extension were 100.0%, 82.6% and 65.7% for 1-, 3-and 5-year survival, respectively; besides, the LRRFS rates of patients with extensive intracranial extension were 88.9%, 52.7% and 31.6% at 1-3-and 5-year survival.
DISEASE-FREE SURVIVAL
As shown in Table 2 , age, the Karnofsky index, intracranial extension and nodal status were each significantly correlated with DFS (all P , 0.05). When age, sex and these three factors were assembled into a multiple Cox proportional hazard model, the effect of the Karnofsky index was disappeared (Table 3) . Comparing to the patients with limited intracranial extension, those with extensive intracranial extension had 3.74 (95% CI ¼ 3.10 -6.66; P , 0.001) times 
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New prognosis in T4 nasopharyngeal carcinoma higher risk of locoregional recurrence, distal metastasis or death. Additionally, relative to patients with nodal status below N2, people whose nodal status at N3 were more likely to have local -regional recurrence, distal metastasis or death (HR ¼ 3.02, 95% CI 1.44 -6.36; P ¼ 0.004). For this outcome measure, the estimated median durations of DFS were 49.0 (SD ¼ 14.5, 95% CI ¼ 20.5 -77.5) months for patients with limited intracranial extension and 13.0 (SD ¼ 4.6, 95% CI ¼ 4.0 -22.0) months for patients with extensive intracranial extension. In addition, the DFS rates of patients with limited intracranial extension were 85.4%, 50.2% and 37.1% for 1-, 3-and 5-year survival, respectively; besides, the DFS rates of patients with extensive intracranial extension were 53.5%, 12.3% and 3.1% at 1-, 3-and 5-year survival (Fig. 2) .
EFFECTS OF CHEMOTHERAPY AND TUMOR HISTOLOGY
We did not find a difference in OS or LRRFS between groups receiving CCRT and those receiving radiotherapy alone (data not shown). Tumor histology in the present patient cohort was mostly that of undifferentiated carcinoma; and this factor, also, did not significantly influence outcome (data not shown).
DISCUSSION
In this study, we evaluated various factors for their prognostic value in patients with Stage T4 NPC. We found that patients whose primary T4 NPC tumors involved only the unilateral cavernous sinus or the parasellar region had a 5-yr OS rate of 42.9% after treatment. In contrast, patients whose T4 tumors extended to the bilateral cavernous sinus or the parasellar region, into the orbit and the ethmoid sinus anteriorly, or to the prepontine region and the posterior cranial fossa had a 5-yr OS rate of only 3.4% after treatment. This difference was significant. There are several possible explanations for this observation. It has been shown that there is a large variation in tumor volume between NPC tumors with different T-staging, and primary tumor volume represents an important prognostic factor and that tumor volume is a more important prognostic factor than T-stage (10, 11, 15) . In our study, the better prognosis of patients with tumors that had limited extension into the cranial area may have reflected the fact they were likely to have had a lower primary tumor volume or that it was less difficult to spare critical organs during radiotherapy. It is currently not possible to conclude whether our results are due to the effects of tumor volume, proximity to critical organs, or other actors. Further studies measuring tumor volume and intracranial extension in patients with T4 tumors are indicated to clarify this point. In any case, it is not always an easy matter to measure tumor volume reproducibly (15) in the clinic; therefore, intracranial extension may be more applicable clinically even if it is only a surrogate for tumor size. It is generally accepted that patients with advanced-stage primary NPC tumors have a worse prognosis than those with early-stage tumors, and more than half of the patients with Stage T4 tumors experience treatment failure after radiotherapy (16) . However, very few investigators analyzed their survival data according to T-stage. The OS in our study was lower than the 5-yr OS reported by Chang et al. (10) for patients with T4 NPC, and our 1-year rate of DFS was lower than the 2-year DFS reported by Kwong et al. (17) for patients with T4 tumors treated with intensity-modulated radiotherapy (IMRT). This variability highlights the problems and confusion that arise while attempting to compare treatment modalities and outcomes when the T-stage confers such a variable prognosis.
We also found that patients in our study with an N3 nodal status were more likely to die, and nodal stage was a prognostic factor for OS in patients with Stage T4 tumors. This is consistent with other reports that despite aggressive radiation treatment of advanced tumors (Stages III and IV), metastasis remains a major problem (1, 8, 18) . In addition to adjuvant chemotherapy (19) , neoadjuvant chemotherapy may also be considered for AJCC 1997 Stage N3 disease to achieve an optimal metastasis-free survival rate (20) .
Our observation that older patients may have a poorer treatment outcome is in agreement with that of Teo et al. (21) who reported an association between advanced patient age and poorer local tumor control and worse survival. This may be a reflection of decreased tolerance of treatment among older patients. Therefore, to reduce morbidity, we 
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New prognosis in T4 nasopharyngeal carcinoma recommend treating older patients cautiously during radiotherapy, especially when combined with chemotherapy.
In the present study, we did not find a difference in OS or LRRFS between groups receiving CCRT and those receiving radiotherapy alone. These results are in agreement with other report (5, 6) . Furthermore, Lin et al. (2) reported that CCRT is inadequate for high-risk patients, including those with AJCC 1992 Stage T4N2 disease and concluded that neoadjuvant and/or adjuvant chemotherapy would be a reasonable approach for these patients. Finally, Jian et al. (22) found better local control of T3 and T4 NPC by hyperfractionated radiotherapy and concomitant chemotherapy.
Our study has several limitations that should be considered. We did not collect data on the presence of co-morbidities; and therefore, any associations between NPC with intracranial involvement and co-morbidities were not elucidated. Because it was retrospective in nature, conventional radiotherapy, as opposed to more current therapies such as three-dimensional conformal radiotherapy or IMRT, was used for treatment of the 84 patients for whom we obtained data. In addition, even though IMRT has become popular in recent years, given its improved radiation dose distribution and conformity of treatment volume (23), there have been no studies regarding this treatment modality and local control or survival for specifically for patients with NPC with intracranial extension. Nevertheless, serious morbidities, including brain necrosis and radiation-induced optic neuropathy, were noted in the present study, which might have been less frequent or severe had a technique such as IMRT been available (17, 24) . Finally, the retrospective nature of the study prevented us from comparing the effects of tumor volume with those of intracranial extension. Such a comparison is warranted in a future study. It would also be of interest to evaluate the efficacy of the more advanced techniques in radiotherapy in the subset of patients with extensive vs. those with limited cranial involvement.
In conclusion, we have shown that patients whose primary nasopharyngeal T4 tumors involved only the unilateral cavernous sinus or the parasellar region had significantly better outcomes after treatment than patients whose T4 tumors extended to the bilateral cavernous sinus or the parasellar region, into the orbit and the ethmoid sinus anteriorly, or to the prepontine region and the posterior cranial fossa. This refinement of the T-staging system may provide a more Figure 2 . Stratified Kaplan -Meier's survival curves of (a) overall survival, (b) locoregional recurrence-free survival and (c) disease-free survival in 84 patients with Stage T4 nasopharyngeal carcinoma in patients with limited or extensive intracranial extension. The P values calculated by the log-rank test were ,0.001 for overall survival rate, 0.001 for locoregional recurrence-free survival and 0.003 for disease-free survival.
uniform tool for determining patient prognosis. We propose adoption of a subdivision of NPC T4 disease based on the extent of intracranial involvement.
